Recommended Use of BayRab®, Rabies Immune Globulin (Human)
Indicated for post-exposure prophylaxis in persons requiring treatment. A regimen including both BayRab® and rabies vaccine will provide both short-term and long-term protection. BayRab® should be administered as promptly as possible after exposure, but may be given through the seventh day after the first dose of rabies vaccine is given. The circumstances of biting incident, type of exposure, vaccination status of biting animal, and presence of rabies in region, should be taken into consideration.
Recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the U.S. Public Health Service Advisory Committee on Immunization Practice (ACIP).
For short-term, passive, transient post-exposure prevention of rabies infection.
For Intramuscular Administration Only.
CONTRAINDICATIONS, SIDE EFFECTS, AND PRECAUTIONS
Use caution in persons with a history of prior systemic allergic reaction to human immune globulin products or a history of IgA deficiency
The most common side effects reported are slight soreness at the site of injection and slight temperature elevation
Administration of live virus vaccines (e.g., MMR) should be deferred for approximately 3 months after rabies immune globulin (human) administration.
Please read the complete prescribing information
contained in the package insert.
Click here for more information.
|
